vTv Therapeutics Inc. (VTVT) stock
Close on Nov 13, 2026Market cap $77.85MP/E –Yield –
vTv Therapeutics Inc. grew revenue 216600.0% to $36.84M over the twelve months to Sep 30, 2026. At the latest close the market valued the company at $77.85M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $77.85M
- P/E ratio
- –
- Price to sales
- 2.11
- Price to book
- 1.12
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $36.84M
- Net income
- -$7.68M
Trading
- Next earnings
- Mar 9, 2027 (estimated, after the close)
- Previous close
- $20.69
- Open
- $20.81
- Day's range
- $19.04 – $20.81
- Volume
- 17,403
- Average volume (20 days)
- 22,156
- Beta (5 years)
- 1.07
- 52-week range
- $19.04 – $44.00
- RSI (14 days)
- 22.8
- Volatility (1 year)
- 71.9%
- Relative volume
- 0.32×
- WACC
- 10.5%
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | VTVT | S&P 500 | Difference | VTVT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -30.3% | -3.0% | −27.2 pts | ||
| 3 months | -36.2% | -2.8% | −33.4 pts | ||
| Year to date | -50.8% | +11.5% | −62.3 pts | ||
| 1 year | -37.0% | +13.5% | −50.5 pts | ||
| 3 years | +38.3% | +77.7% | −39.4 pts | +11.4% | +21.1% |
| 5 years | -68.0% | +72.6% | −140.6 pts | -20.4% | +11.5% |
| 10 years | -90.0% | +308.2% | −398.2 pts | -20.6% | +15.1% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
Free cash flow
Press releases
Releases vTv Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Results
- Update
About vTv Therapeutics
Pharmaceutical Preparations
The company is a clinical-stage biopharmaceutical firm that discovers and develops oral therapies for metabolic and inflammatory conditions. Its primary drug candidate is cadisegliatin, an oral liver-selective glucokinase activator in late-stage development as an add-on treatment to insulin for individuals with type 1 and type 2 diabetes. Its broader research pipeline features oral small molecules including a GLP-1 receptor agonist for diabetes management, a preclinical RAGE antagonist, Nrf2 pathway activators for inflammation, and a globally licensed PDE4 inhibitor. The company targets patients suffering from chronic metabolic and autoimmune disorders, while collaborating with commercial partners and research institutions.
Company profile, executives and historyvTv Therapeutics stock: common questions
What is vTv Therapeutics's stock price?
VTVT closed at $19.69 on Nov 13, 2026, down 4.83% on the day. Over the past 52 weeks it traded between $19.04 and $44.00.
What is vTv Therapeutics's market cap?
vTv Therapeutics was worth $77.85M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
How much revenue does vTv Therapeutics make?
vTv Therapeutics reported revenue of $36.84M for the twelve months to Sep 30, 2026, up 216600.0% from a year earlier.
Does vTv Therapeutics pay a dividend?
No. vTv Therapeutics has not paid a cash dividend over the last twelve months.
When does vTv Therapeutics report earnings next?
vTv Therapeutics is expected to report Q4 FY2026 results on Mar 9, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has VTVT stock performed over the past year?
Including dividends, VTVT returned -37.0% over the past year, against +13.5% for the S&P 500.
How many VTVT shares are sold short?
0M shares were sold short at the latest FINRA report, 4.99% of the float, or 8.2 days of average trading volume.
Who are vTv Therapeutics's competitors?
Companies most similar to vTv Therapeutics by business, industry and size include NAMS, VRDN, LXRX, ROIV, KROS.
See a number that looks wrong?